A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. [artículo]
Por: Cortés-Funes Castro, Hernán [Oncología Médica]
| Grávalos Castro, Cristina [Oncología Médica].
Colaborador(es): Servicio de Oncología Médica.
Editor: Clinical & Translational Oncology, 2012Descripción: 14(8):606-12.Recursos en línea: Solicitar documento Resumen: The aim of this study was to compare TOMOX versus FOLFOX4 as first-line treatment of advanced colorectal cancer (CRC).
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC2933 (Navegar estantería) | Disponible |
Formato Vancouver:
Gravalos C, Salut A, García-Girón C, García-Carbonero R, León AI, Sevilla I, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4)
versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol. 2012 Aug;14(8):606-12.
PMID: 22855138
Contiene 34 referencias
The aim of this study was to compare TOMOX versus FOLFOX4 as first-line treatment of advanced colorectal cancer (CRC).
No hay comentarios para este ejemplar.